GLP-1R is a class B GPCR and a major therapeutic target for type 2 diabetes and obesity.  Several GLP-1 analog drugs have been approved for T2DM to achieve excellent glycemic control and improved β-cell function with hypoglycemia rarely.  However, the on-target toxicity limited their dosage and any further improvement to the patients.


GMA102/105 is a humanized anti-GLP-1R monoclonal antibody carrying a GLP-1 fragment, potentially to overcome the shortcomings of the existing drugs. It could serve as a biased GLP-1 in the hope of having less on-target toxicity.  


GMA102/105 is currently in phase 2 clinical trials in Australia and New Zealand.